Live Breaking News & Updates on Stoke Therapeutics|Page 3

Stay updated with breaking news from Stoke therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $20.00 at Canaccord Genuity Group

Stoke Therapeutics (NASDAQ:STOK) Price Target Lowered to $20.00 at Canaccord Genuity Group
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

United States , Stephenj Tulipano , Mirae Asset Global Investments Co , Securities Exchange Commission , Cantor Fitzgerald , Corton Capital Inc , Jpmorgan Chase Co , Stoke Therapeutics Inc , Capital Partners , Canaccord Genuity Group , Stoke Therapeutics Company Profile , Stoke Therapeutics , Get Free Report , Genuity Group , Exchange Commission , Asset Global Investments , Public Employees Retirement System , Stoke Therapeutics Daily ,

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

– Recent data demonstrating reductions in seizure frequency and improvements in cognition and behavior support the potential for STK-001 as a disease-modifying potential medicine for the treatment. ....

United Kingdom , United States , Edwardm Kaye , Thomas Tommy Leggett , Association For Research , Company Annual Report On Form , American Society Of Gene , Exchange Commission , Acadia Pharmaceuticals , Stoke Therapeutics Inc , Augmentation Of Nuclear Gene Output , Stoke Therapeutics , Chief Executive Officer , Program Highlights , Seventeenth Eilat Conference , New Antiepileptic Drugs , American Society , Cell Therapy , Autosomal Dominant Optic Atrophy , Jason Hoitt , Chief Commercial Officer , Chief Financial , Collaboration Agreement , Targeted Augmentation , Nuclear Gene Output , Private Securities Litigation Reform Act ,

Stoke Therapeutics (NASDAQ:STOK) Stock Rating Reaffirmed by Needham & Company LLC

Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “buy” rating restated by analysts at Needham & Company LLC in a note issued to investors on Monday, Benzinga reports. They currently have a $22.00 price target on the stock. Needham & Company LLC’s price target would indicate a potential upside of 80.33% from the […] ....

United States , Stephenj Tulipano , Securities Exchange Commission , Stoke Therapeutics Inc , Sherbrooke Park Advisers , Corton Capital Inc , Dorsey Whitney Trust , Cantor Fitzgerald , Needham Company , Jpmorgan Chase Co , Canaccord Genuity Group , Sg Americas Securities , Stoke Therapeutics , Get Free Report , Exchange Commission , Whitney Trust , Park Advisers , Public Employees Retirement System , Stoke Therapeutics Daily , Nasdaq Stok , Reiterated Rating , Needham Company Llc ,

STOK Stock Earnings: Stoke Therapeutics Beats EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips STOK stock results show that Stoke Therapeutics beat analyst estimates for earnings per share… ....

Market News , Stock Advice , Stoke Therapeutics , Stoke Therapeutics Beats , Beats Revenue , Reaking News ,

Stoke Therapeutics : Corporate Presentation - May 2024

Stoke Therapeutics : Corporate Presentation - May 2024
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Exchange Commission , Stoke Therapeutics Inc , Stoke Therapeutics , Private Securities Litigation Reform Act , Middle East , Annual Report ,